Healthcare Industry Business Confidence Report 2019
Summary
GlobalData's "Healthcare Industry Business Confidence Report 2019", examines executives' opinion about the business environment during 2019. It also highlights current economic conditions, supplier price variations, sales performance, industry and company growth prospects, spending models, and key priorities. Additionally, the report provides information categorized by region, and company size and type.
The majority of respondents see the current global economic situation as stable or favorable. North American and Asia-Pacific economies were viewed as most favorable but respondents from these regions had less favorable views of the global economy. Factors such as reduced mortality, aging population, advances in biomedical engin......
|
$1950 |
|
Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027
Summary
Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD) is one of the many complications associated with overall CKD. The systemic disorder is identified from high parathyroid hormone and disrupted K+/Ca2+ levels caused by a decreasing glomerular filtration rate (GFR) due to renal impairment.
This report provides an assessment of the pipeline, clinical, and commercial landscape of CKD-MBD. Overall, GlobalData expects minimal changes to overall disease treatment, with exceptions being the launch of the novel NHE3 and novel CASR in the US and Japan markets respectively.
Scope
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clini......
|
$3495 |
|
Chimeric Antigen Receptor Cell Therapy
Summary
Chimeric antigen receptor (CAR) cell therapy is an immuno-oncology (IO) approach that has gained increasing momentum in the past few years, with the approval of two new therapies in 2017 (US) and 2018 (EU). Novartis' Kymriah (tisagenlecleucel) and Gilead Sciences' Yescarta (axicabtagene ciloleucel) demonstrated impressive efficacy, and have both been approved for diffuse large B-cell lymphoma (DLBCL), with Novartis' product approved for acute lymphocytic leukemia as well. Despite promising efficacy data, several challenges face the integration of CAR cell therapies into the clinic. Complex manufacturing can lead to delayed patient access, as currently approved therapies can take up to three weeks to manufacture. High toxicity is also a key c......
|
$7995 |
|
Company Profile: 23andMe
Summary
23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information.
Scope
The report provides information and insights into 23andMe, including -
- Overview of the company and its product offering
- Detailed insight into its business operation, technology, revenue model, geographical presence and business model
- Information on partnerships, funding and awards it received
- Biography of top management.
Reasons to buy
- Gain insights into 23andMe's business operations.
- Gain insights into funding and partnerships.
- Gain understanding about its technology focus and success ......
|
$350 |
|
Company Profile: Fitbit, Inc.
Summary
Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc.
Scope
The report provides information and insights into Fitbit, Inc., including -
- Overview of the company and its product offering
- Detailed insight into its business operation, technology, revenue model, geographical presence and business model
- Information on partnerships, funding and awards it received
- Biography of top management.
Reasons to buy
- Gain insights into Fitbit business operations.
- Gain insights into funding and partnerships.
- Gain understanding about its technology focus and success factors.......
|
$350 |
|
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India
Summary
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
|
$1995 |
|
The State of the Microbiome
Summary
GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space.
Scope
- Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area
- Identify the challenges associated with
- Developing microbiome therapeutics
- Launching microbiome therapeutics
- Manufacturing microbiome therapeutics.
Reasons to buy
- Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
|
$1495 |
|
Rheumatoid Arthritis: Epidemiology Forecast to 2027
Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.
GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06.
In 2......
|
$3995 |
|
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
|
$1500 |
|
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China
Summary
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
|
$1995 |
|
